• Price (MXN)3,233.10
  • Today's Change-0.01 / 0.00%
  • Shares traded14.00
  • 1 Year change+26.79%
  • Beta--
Data delayed at least 20 minutes, as of Dec 07 2022 15:05 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

  • Revenue in USD (TTM)57.82bn
  • Net income in USD13.34bn
  • Incorporated2012
  • Employees50.00k
  • Location
    Abbvie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
  • Phone+1 (847) 932-7900
  • Fax+1 (302) 655-5049
  • Websitehttps://www.abbvie.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ABBV:NYQ since
DJS Antibodies LtdDeal completed20 Oct 202220 Oct 2022Deal completed14.41%255.00m
iSTAR Medical SAAnnounced20 Jul 202220 Jul 2022Announced9.36%475.00m
Syndesi Therapeutics SADeal completed01 Mar 202201 Mar 2022Deal completed10.81%1.00bn
Data delayed at least 15 minutes, as of Dec 07 2022 16:53 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.